Circulating sRANKL, Periostin, and Osteopontin as Biomarkers for the Assessment of Activated Osteoclastogenesis in Myeloma Related Bone Disease
Author:
Gerov Vladimir1ORCID, Gerova Daniela2, Micheva Ilina13, Nikolova Miglena4ORCID, Pasheva Milena4, Nazifova Neshe4, Galunska Bistra4
Affiliation:
1. Clinics of Hematology, “St. Marina” University Hospital, 9010 Varna, Bulgaria 2. Department of Clinical Laboratory, Faculty of Medicine, MU Varna, 9002 Varna, Bulgaria 3. Second Department of Internal Disease, Faculty of Medicine, MU Varna, 9002 Varna, Bulgaria 4. Department of Biochemistry, Molecular Medicine and Nutrigenomics, Faculty of Pharmacy, MU Varna, 9000 Varna, Bulgaria
Abstract
The hallmark of multiple myeloma is myeloma related bone disease. Interactions between myeloma plasma cells (MPCs), stromal cells, and the bone marrow (BM) microenvironment play a critical role in the pathogenesis of MBD. Bone remodeling is severely dysregulated with the prevalence of osteoclast activity. We aimed to assess circulating levels of sRANKL, periostin, and osteopontin as osteoclast activators in NDMM patients at diagnosis and in the course of treatment, correlations with clinical and laboratory data, and to evaluate their potential as additional biomarkers for the assessment of MBD. The current study involved 74 subjects (41 NDMM patients, 33 controls). MBD was assessed by whole-body low-dose computed tomography. sRANKL, periostin, and osteopontin were assayed by commercial ELISA kits. At diagnosis, all tested parameters were significantly higher in NDMM patients compared to the controls (p < 0.0001), correlating with disease stage, MBD grade, and BM infiltration by MPCs. During therapy, the serum levels of all tested proteins decrease, most prominently after autologous stem cell transplantation (p < 0.0001). A significant reduction was established in patients achieving complete and very-good partial response compared to all others (p < 0.05). In conclusion, sRANKL, periostin, and osteopontin reflect MBD severity and could be promising markers for MBD monitoring and the effect of myeloma treatment.
Funder
Fund “Science”, Medical University of Varna
Subject
Cancer Research,Oncology
Reference71 articles.
1. Padala, S.A., Barsouk, A., Barsouk, A., Rawla, P., Vakiti, A., Kolhe, R., Kota, V., and Ajebo, G.H. (2021). Epidemiology, Staging, and Management of Multiple Myeloma. Med. Sci., 9. 2. Multiple Myeloma: Every Year a New Standard?;Rajkumar;Hematol. Oncol.,2019 3. Pathogenesis of Bone Disease in Multiple Myeloma: From Bench to Bedside;Terpos;Blood Cancer J.,2018 4. Burden of Disease Progression in Patients with Multiple Myeloma in the US;Hagiwara;Leuk. Lymphoma,2020 5. The Bone Marrow Microenvironment in Health and Disease at a Glance;Kumar;J. Cell Sci.,2018
|
|